{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T05:05:38Z","timestamp":1785215138405,"version":"3.55.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["20230484407"],"award-info":[{"award-number":["20230484407"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005090","name":"Beijing Nova Program","doi-asserted-by":"publisher","award":["2023hqzz09"],"award-info":[{"award-number":["2023hqzz09"]}],"id":[{"id":"10.13039\/501100005090","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7222175"],"award-info":[{"award-number":["7222175"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFA1100904"],"award-info":[{"award-number":["2021YFA1100904"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2507800"],"award-info":[{"award-number":["2023YFC2507800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270224"],"award-info":[{"award-number":["82270224"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200169"],"award-info":[{"award-number":["82200169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82270162"],"award-info":[{"award-number":["82270162"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Pathogenesis and Therapy"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cpt.2025.04.001","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T18:47:10Z","timestamp":1744051630000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Reduced cytomegalovirus reactivation and viremia following unrelated donor peripheral blood stem cell transplantation (URD-PBSCT) with targeted anti-thymocyte globulin (ATG) dosing: A prospective study"],"prefix":"10.1016","volume":"4","author":[{"given":"Sheng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songhua","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haitao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jishan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongxue","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongli","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liping","family":"Dou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3334-9113","authenticated-orcid":false,"given":"Daihong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpt.2025.04.001_bib1","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1038\/s41409-023-02095-0","article-title":"The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP\/EBMT","volume":"58","author":"Nagler","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib2","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1200\/JCO.20.01771","article-title":"Optimizing donor choice and GVHD prophylaxis in allogeneic hematopoietic cell transplantation","volume":"39","author":"Holtan","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.cpt.2025.04.001_bib3","first-page":"1265","article-title":"Antithymocyte globulin for GVHD prophylaxis in allogeneic hematopoietic stem cell transplantation (in Japanese)","volume":"62","author":"Shiratori","year":"2021","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.cpt.2025.04.001_bib4","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s40262-023-01252-4","article-title":"Population pharmacokinetics of total rabbit anti-thymocyte globulin in non-obese adult patients undergoing hematopoietic cell transplantation for hematologic malignancy","volume":"62","author":"Takahashi","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cpt.2025.04.001_bib5","article-title":"Therapeutic drug monitoring of conditioning agents in pediatric allogeneic stem cell transplantation; where do we stand?","volume":"13","author":"Oostenbrink","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.cpt.2025.04.001_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(20)30181-2","article-title":"Anti-thymocyte globulin for GVHD: one dose does not fit all","volume":"7","author":"Admiraal","year":"2020","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpt.2025.04.001_bib7","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(17)30029-7","article-title":"Association between anti-thymocyte globulin exposure and survival outcomes in adult unrelated haemopoietic cell transplantation: a multicentre, retrospective, pharmacodynamic cohort analysis","volume":"4","author":"Admiraal","year":"2017","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpt.2025.04.001_bib8","doi-asserted-by":"crossref","first-page":"e111","DOI":"10.1016\/S2352-3026(21)00375-6","article-title":"Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial","volume":"9","author":"Admiraal","year":"2022","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpt.2025.04.001_bib9","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.bbmt.2020.02.026","article-title":"Does lymphocyte count impact dosing of anti-thymocyte globulin in unrelated donor stem cell transplantation?","volume":"26","author":"Heelan","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib10","first-page":"e1","article-title":"Optimal active anti-thymocyte globulin exposure associated with minimum risk of virus reactivation and comparable acute graft-versus-host disease under adult myeloablative haploidentical peripheral blood stem cell transplantation","volume":"28","author":"Wang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cpt.2025.04.001_bib11","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1002\/ajh.27068","article-title":"Targeted dosing of anti-thymocyte globulin in adult unmanipulated haploidentical peripheral blood stem cell transplantation: a single-arm, phase 2 trial","volume":"98","author":"Wang","year":"2023","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpt.2025.04.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2022.101035","article-title":"Haploidentical transplants with a G-CSF\/ATG-based protocol: experience from China","volume":"62","author":"Xu","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.cpt.2025.04.001_bib13","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","article-title":"Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"10.1016\/j.cpt.2025.04.001_bib14","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2147\/IDR.S225465","article-title":"Protective effects of cytomegalovirus DNA copies \u22651000\/mL for AML patients in complete remission after single cord blood transplantation","volume":"13","author":"Dong","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.cpt.2025.04.001_bib15","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00277-020-04156-6","article-title":"Risk factors and associations with clinical outcomes of cytomegalovirus reactivation after haploidentical versus matched-sibling unmanipulated PBSCT in patients with hematologic malignancies","volume":"99","author":"Gao","year":"2020","journal-title":"Ann Hematol"},{"key":"10.1016\/j.cpt.2025.04.001_bib16","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jtct.2021.04.007","volume":"27","author":"Kharfan-Dabaja","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.cpt.2025.04.001_bib17","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1038\/s41409-024-02251-0","article-title":"Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT","volume":"59","author":"Sureda","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13287-024-03726-z","article-title":"Graft failure after allogeneic hematopoietic stem cell transplantation in pediatric patients with acute leukemia: autologous reconstitution or second transplant?","volume":"15","author":"Rostami","year":"2024","journal-title":"Stem Cell Res Ther"},{"key":"10.1016\/j.cpt.2025.04.001_bib19","doi-asserted-by":"crossref","first-page":"4479","DOI":"10.1182\/bloodadvances.2023009885","article-title":"Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD","volume":"7","author":"Akahoshi","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.cpt.2025.04.001_bib20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1182\/hematology.2021000301","article-title":"Updates in chronic graft-versus-host disease","volume":"2021","author":"Hamilton","year":"2021","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.cpt.2025.04.001_bib21","first-page":"217","article-title":"Current status and progresses of cytomegalovirus infection management after hematopoietic stem cell transplantation in China (in China)","volume":"63","author":"Xu","year":"2024","journal-title":"Chin J Intern Med"},{"key":"10.1016\/j.cpt.2025.04.001_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217264","article-title":"Consensus on the monitoring, treatment, and prevention of leukaemia relapse after allogeneic haematopoietic stem cell transplantation in China: 2024 update","volume":"605","author":"Wang","year":"2024","journal-title":"Cancer Lett"},{"key":"10.1016\/j.cpt.2025.04.001_bib23","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/S2352-3026(23)00344-7","article-title":"Efficacy and safety of extended duration letermovir prophylaxis in recipients of haematopoietic stem-cell transplantation at risk of cytomegalovirus infection: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Russo","year":"2024","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.cpt.2025.04.001_bib24","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/v16081268","article-title":"Antiviral agents for preventing cytomegalovirus disease in recipients of hematopoietic cell transplantation","volume":"16","author":"Jaing","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.cpt.2025.04.001_bib25","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/bmt.2013.191","article-title":"Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial","volume":"49","author":"Wang","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib26","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1097\/01.TP.0000133513.29923.44","article-title":"Dose study of thymoglobulin during conditioning for unrelated donor allogeneic stem-cell transplantation","volume":"78","author":"Remberger","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.cpt.2025.04.001_bib27","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s12916-019-1393-7","article-title":"Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study","volume":"17","author":"Lin","year":"2019","journal-title":"BMC Med"},{"key":"10.1016\/j.cpt.2025.04.001_bib28","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.1002\/cncr.30540","article-title":"Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: long-term outcomes of a prospective randomized trial","volume":"123","author":"Chang","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.cpt.2025.04.001_bib29","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/s41409-022-01754-y","volume":"57","author":"Zu","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib30","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1080\/10428194.2017.1390234","article-title":"Low dose anti-thymocyte globulin reduces chronic graft-versus-host disease incidence rates after matched unrelated donor transplantation","volume":"59","author":"Tandra","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cpt.2025.04.001_bib31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0284476","article-title":"Systematic review and meta-analysis of anti-thymocyte globulin dosage as a component of graft-versus-host disease prophylaxis","volume":"18","author":"Zuckermann","year":"2023","journal-title":"PLoS One"},{"key":"10.1016\/j.cpt.2025.04.001_bib32","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/j.bbmt.2019.03.023","article-title":"Pharmacological considerations in antithymocyte globulin exposure calculation","volume":"25","author":"Admiraal","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.bbmt.2017.11.020","article-title":"Antithymocyte globulin: steps toward individualized dosing","volume":"24","author":"Admiraal","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib34","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1136\/archdischild-2013-303721","article-title":"Towards evidence-based dosing regimens in children on the basis of population pharmacokinetic pharmacodynamic modelling","volume":"99","author":"Admiraal","year":"2014","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.cpt.2025.04.001_bib35","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41409-024-02206-5","article-title":"Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience","volume":"59","author":"Barriga","year":"2024","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.cpt.2025.04.001_bib36","doi-asserted-by":"crossref","first-page":"1023.e1","DOI":"10.1016\/j.jtct.2024.07.023","article-title":"Patients beyond the optimal range of rATG-AUC still benefit from the targeted dosing strategy in unmanipulated haplo-PBSCT","volume":"30","author":"Du","year":"2024","journal-title":"Transplant Cell Ther"}],"container-title":["Cancer Pathogenesis and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713225000369?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949713225000369?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:23:54Z","timestamp":1773505434000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949713225000369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S2949713225000369"],"URL":"https:\/\/doi.org\/10.1016\/j.cpt.2025.04.001","relation":{},"ISSN":["2949-7132"],"issn-type":[{"value":"2949-7132","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced cytomegalovirus reactivation and viremia following unrelated donor peripheral blood stem cell transplantation (URD-PBSCT) with targeted anti-thymocyte globulin (ATG) dosing: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Cancer Pathogenesis and Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cpt.2025.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier B.V. on behalf of Chinese Medical Association (CMA).","name":"copyright","label":"Copyright"}]}}